AU2012240508B2 - Antibodies that bind TGF-alpha and Epiregulin - Google Patents

Antibodies that bind TGF-alpha and Epiregulin Download PDF

Info

Publication number
AU2012240508B2
AU2012240508B2 AU2012240508A AU2012240508A AU2012240508B2 AU 2012240508 B2 AU2012240508 B2 AU 2012240508B2 AU 2012240508 A AU2012240508 A AU 2012240508A AU 2012240508 A AU2012240508 A AU 2012240508A AU 2012240508 B2 AU2012240508 B2 AU 2012240508B2
Authority
AU
Australia
Prior art keywords
ser
val
thr
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012240508A
Other languages
English (en)
Other versions
AU2012240508A1 (en
Inventor
Catherine Brautigam Beidler
Josef George Heuer
Ramona Judita Petrovan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2012240508A1 publication Critical patent/AU2012240508A1/en
Application granted granted Critical
Publication of AU2012240508B2 publication Critical patent/AU2012240508B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012240508A 2011-04-06 2012-03-28 Antibodies that bind TGF-alpha and Epiregulin Ceased AU2012240508B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472338P 2011-04-06 2011-04-06
US61/472,338 2011-04-06
PCT/US2012/030802 WO2012138510A1 (en) 2011-04-06 2012-03-28 Antibodies that bind tgf-alpha and epiregulin

Publications (2)

Publication Number Publication Date
AU2012240508A1 AU2012240508A1 (en) 2013-08-29
AU2012240508B2 true AU2012240508B2 (en) 2014-10-23

Family

ID=45929050

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012240508A Ceased AU2012240508B2 (en) 2011-04-06 2012-03-28 Antibodies that bind TGF-alpha and Epiregulin

Country Status (26)

Country Link
US (1) US8613921B2 (enExample)
EP (1) EP2694547B1 (enExample)
JP (1) JP2014515743A (enExample)
KR (1) KR101581517B1 (enExample)
CN (1) CN103459423B (enExample)
AR (2) AR085484A1 (enExample)
AU (1) AU2012240508B2 (enExample)
BR (1) BR112013023513A2 (enExample)
CA (1) CA2832256C (enExample)
CY (1) CY1116332T1 (enExample)
DK (1) DK2694547T3 (enExample)
EA (1) EA024921B1 (enExample)
ES (1) ES2539503T3 (enExample)
HR (1) HRP20150468T1 (enExample)
IL (1) IL228101A0 (enExample)
ME (1) ME02063B (enExample)
MX (1) MX2013011596A (enExample)
PL (1) PL2694547T3 (enExample)
PT (1) PT2694547E (enExample)
RS (1) RS54000B1 (enExample)
SG (1) SG193452A1 (enExample)
SI (1) SI2694547T1 (enExample)
TW (1) TWI454481B (enExample)
UA (1) UA110051C2 (enExample)
WO (1) WO2012138510A1 (enExample)
ZA (1) ZA201306813B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
TWI807338B (zh) * 2020-06-26 2023-07-01 美商美國禮來大藥廠 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
KR102495473B1 (ko) * 2020-10-06 2023-02-06 서울대학교병원 앰피레귤린을 유효성분으로 포함하는 안질환 치료용 조성물
TWI859538B (zh) 2021-05-21 2024-10-21 美商美國禮來大藥廠 靶向表皮調節素(epiregulin)之化合物及方法
CN119213026A (zh) * 2022-03-04 2024-12-27 耶鲁大学 用于治疗和预防纤维化的方法和组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436397A1 (en) * 2009-05-29 2012-04-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition containing antagonist of egf family ligand as component

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190858A (en) 1989-02-01 1993-03-02 Oncogene Science, Inc. Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof
JP5919593B2 (ja) 2006-10-11 2016-05-18 フージョン アンティボディーズ リミテッド 併用療法
RU2537245C2 (ru) 2006-10-12 2014-12-27 Чугаи Сейяку Кабусики Кайся Диагностика и лечение злокачественной опухоли с использованием антитела против ereg
GB0807018D0 (en) * 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436397A1 (en) * 2009-05-29 2012-04-04 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition containing antagonist of egf family ligand as component

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PANCHAPAKESAN U, et al. Clinical and Experimental Pharmacology and Physiology, (2011) Vol 38, pp 84-88. *

Also Published As

Publication number Publication date
US20120258109A1 (en) 2012-10-11
CA2832256C (en) 2016-02-09
DK2694547T3 (en) 2015-04-27
EA201370196A1 (ru) 2014-02-28
UA110051C2 (uk) 2015-11-10
RS54000B1 (sr) 2015-10-30
IL228101A0 (en) 2013-09-30
PL2694547T3 (pl) 2015-08-31
JP2014515743A (ja) 2014-07-03
MX2013011596A (es) 2013-12-09
KR101581517B1 (ko) 2015-12-30
PT2694547E (pt) 2015-06-01
EP2694547A1 (en) 2014-02-12
TW201300414A (zh) 2013-01-01
KR20130133274A (ko) 2013-12-06
AR085484A1 (es) 2013-10-02
SG193452A1 (en) 2013-10-30
CY1116332T1 (el) 2017-02-08
HRP20150468T1 (hr) 2015-06-05
AU2012240508A1 (en) 2013-08-29
WO2012138510A1 (en) 2012-10-11
ZA201306813B (en) 2015-04-29
SI2694547T1 (sl) 2015-05-29
CN103459423A (zh) 2013-12-18
NZ614198A (en) 2015-09-25
ME02063B (me) 2015-05-20
AR123912A2 (es) 2023-01-25
ES2539503T3 (es) 2015-07-01
EA024921B1 (ru) 2016-11-30
US8613921B2 (en) 2013-12-24
TWI454481B (zh) 2014-10-01
BR112013023513A2 (pt) 2016-11-22
CA2832256A1 (en) 2012-10-11
HK1190410A1 (en) 2014-07-04
CN103459423B (zh) 2016-03-02
EP2694547B1 (en) 2015-03-18

Similar Documents

Publication Publication Date Title
KR102553870B1 (ko) 인간 카나비노이드 1(cb1) 수용체 결합 항체
DK2694547T3 (en) Antibodies that bind TGF-ALPHA AND epiregulin
JP7558306B2 (ja) 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体
AU2016330471A1 (en) Antibodies that bind human cannabinoid 1 (CB1) receptor
AU2009322587B2 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
US9695241B2 (en) Ang2 antibodies
CN112175087A (zh) 一种抗CD4和TGFβ的双特异性抗体、其药物组合及其用途
CN106573059A (zh) 接受过抗TNF‑α抗体疗法的银屑病患者的治疗方法
NZ614198B2 (en) Antibodies that bind tgf-alpha and epiregulin
HK1190410B (en) Antibodies that bind tgf-alpha and epiregulin
CN114316046B (zh) 一种稳定的抗体组合物
TW202612732A (zh) 抗ＩＬ－１１Ｒα抗體在治療特發性肺纖維化中之給藥
CN119548621A (zh) 抗igf-1r抗体或其抗原结合部分在减重中的应用
TW202334214A (zh) 抗il-17/vegf雙功能融合蛋白及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired